NON-SELECTIVE BETA-BLOCKERS IN CIRRHOTIC PATIENTS WITH REFRACTORY ASCITES: WHERE ARE WE?
| Autor: | Maia AG; Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil., Palhares LFN; Universidade Federal do Rio Grande do Norte, Natal, RN, Brasil., Maia IG; Universidade de Pernambuco, Recife, PE, Brasil., Braulino PDM; Universidade de Pernambuco, Recife, PE, Brasil., Pereira LMMB; Universidade de Pernambuco, Recife, PE, Brasil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Arquivos de gastroenterologia [Arq Gastroenterol] 2024 Jul 19; Vol. 61, pp. e23157. Date of Electronic Publication: 2024 Jul 19 (Print Publication: 2024). |
| DOI: | 10.1590/S0004-2803.24612023157 |
| Abstrakt: | Background: The established use of non-selective beta-blockers (NSBB) in the primary and secondary prevention of esophageal varices has recently been questioned in the subgroup of patients with diuretic-refractory ascites. Objective: Critically analyze the body of evidence on the topic in order to assist clinical decisions. Methods: A literature review was carried out in the Pubmed® and Scielo® databases. In total, 20 articles between 2010 and 2023 were read by independent researchers. Conclusion: It remains doubtful whether the use of NSBB is deleterious in cirrhotic patients with refractory ascites, however our literature review allows us to conclude that these drugs should not be proscribed in these patients. On the contrary, a doctor-patient decision based on tolerability and hemodynamic parameters certainly seems to be a safe conduct. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|